Aghavni Ginosyan

Aghavni Ginosyan

Auto-generated profile, based on publicly available information

Aghavni Ginosyan

Department of Pharmacy, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
RSRaphaël Saporta
Raphaël Saporta
NTNatália Tassi
Natália Tassi
VBVeronica Biordi
Veronica Biordi
OTOlga Ticha
Olga Ticha
AGAghavni Ginosyan
Aghavni Ginosyan
LFLena E. Friberg
Lena E. Friberg
In vivo antibiotic pharmacokinetic-pharmacodynamic (PKPD) properties are typically studied in neutropenic infection models, limiting the understanding of interactions between immune cells and antibiotics. This study aimed to characterize the impact of immune status on meropenem PKPD and dose-response in a mouse lung infection model, and to quantify the relative contribution of immune response and meropenem to bacterial killing. Meropenem PK was analyzed in plasma and epithelial lung fluid, and bacterial counts were monitored over 24 h following 40 or 300 mg/kg meropenem doses every 4 h in a mouse lung infection model with varying immunosuppression levels (neutropenic, intermediate, or immunocompetent). A PKPD model was developed to quantify bacterial killing by the immune response and meropenem over time. Dose-fractionation studies were simulated to investigate meropenem dose-response in different immune states. Observed differences in meropenem concentration-time profiles were explained by a higher volume of distribution in immunocompetent mice. The immune response was described by phagocytosis and digestion processes. The meropenem effect was best quantified based on plasma concentrations, with a maximal killing rate of 0.934 h −1 and EC 50 = 1.62 mg/L. The lower contribution of meropenem to bacterial killing in intermediate and immunocompetent conditions was explained as a lower fraction of bacteria being affected by meropenem. In simulations, the immune status impacted PKPD target derivation. The developed model characterized differences in meropenem PK between neutropenic and immunocompetent in vivo infection models and quantified the contributions of immune response and meropenem to bacterial killing, with a reduced effect of meropenem in immunocompetent systems.

29 July 2026 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
AOAmaury O’JEanson
Amaury O’JEanson
ENElisabet Nielsen
Elisabet Nielsen
ZAZoe Athanassa
Zoe Athanassa
AGAghavni Ginosyan
Aghavni Ginosyan
KIKonstantinos Ioannidis
Konstantinos Ioannidis
LFLena E. Friberg
Lena E. Friberg
To characterise the pharmacokinetics (PK) of ceftazidime-avibactam (CAZ-AVI) and explore the dynamics of a broad blood immune biomarker panel in critically ill patients with hospital-acquired (HAP) or ventilator-associated pneumonia (VAP) caused by Klebsiella pneumoniae. Population PK (PopPK) models were developed for CAZ and AVI individually and jointly, evaluating covariate effects and correlations at interindividual (IIV) and residual unexplained variability (RUV) levels. Biomarker turnover dynamics in blood were modelled, and exposure-biomarker relationships were assessed. The dataset included 266 drug plasma concentration measurements and 48-87 observations per biomarker, collected from ten critically ill patients. CAZ and AVI PK were well-described by two-compartment models, with estimated creatinine clearance (eCrCL) as a key covariate on clearance. Joint modelling revealed significant correlations between the two drugs at both IIV and RUV levels, supporting coherent patient-specific simulations. Turnover dynamics were characterised for 32 biomarkers. The most pronounced biomarker changes over the course of treatment were decreases in IL6, CRP, and AREG, and increases in DCBLD2, LAMP3, and TRIM21. A significant exposure-response relationship was identified between CAZ plasma concentrations and CRP turnover, with higher CAZ levels associated with inhibition of CRP production. The joint PopPK model confirmed eCrCL as a key covariate for clearance. Changes in 32 immune response biomarkers were quantified, with CRP showing a clear exposure-response relationship. These findings provide a foundation for prioritising biomarkers for future studies to guide therapeutic strategies in critically ill patients with HAP or VAP.